WO2003007908A2 - Kosmetische oder dermatologische zubereitungen mit langanhaltender kühlender wirkung - Google Patents
Kosmetische oder dermatologische zubereitungen mit langanhaltender kühlender wirkung Download PDFInfo
- Publication number
- WO2003007908A2 WO2003007908A2 PCT/EP2002/007784 EP0207784W WO03007908A2 WO 2003007908 A2 WO2003007908 A2 WO 2003007908A2 EP 0207784 W EP0207784 W EP 0207784W WO 03007908 A2 WO03007908 A2 WO 03007908A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparations
- polyethylene glycol
- substances
- acid
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/244—Endothermic; Cooling; Cooling sensation
Definitions
- the present invention relates to cosmetic and dermatological preparations with a long-lasting cooling effect, in particular skin-care cosmetic and dermatological preparations.
- the skin is the largest human organ. Among its many functions (for example for heat regulation and as a sensory organ), the barrier function that prevents the skin (and ultimately the entire organism) from drying out is probably the most important. At the same time, the skin acts as a protective device against the penetration and absorption of substances coming from outside. This barrier function is brought about by the epidermis, which as the outermost layer forms the actual protective cover against the environment. At around a tenth of the total thickness, it is also the thinnest layer of the skin.
- the outermost layer of the epidermis is of particular importance as an important barrier layer. for protection against environmental influences and dehydration.
- the horny layer is constantly worn out in contact with the environment and must therefore be renewed continuously.
- the corneocytes homo cells
- the complex lipid membrane in the intercellular spaces corresponds to the mortar.
- the epidermal lipids In addition to their barrier effect against external chemical and physical influences, the epidermal lipids also contribute to the cohesion of the horny layer and have an influence on the smoothness of the skin. In contrast to the sebum lipids, which do not form a closed film on the skin, the epidermal lipids are distributed over the entire horny layer.
- Cosmetic skin care is primarily understood to mean that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, natural fats, electrolytes) is strengthened or restored.
- environmental influences e.g. dirt, chemicals, microorganisms
- loss of the body's own substances e.g. water, natural fats, electrolytes
- the aim of skin care is also to compensate for the loss of fat and water in the skin caused by daily washing. This is especially important when the natural regeneration ability is insufficient.
- skin care products are intended to protect against environmental influences, particularly sun and wind, and to delay skin aging.
- Medical topical compositions usually contain one or more drugs in effective concentration.
- Common cosmetic dosage forms are emulsions, that is, metastable two- or multi-phase systems in which the individual phases are in the liquid state.
- the most common emulsions are O / W and W / O emulsions.
- More rare forms of administration are multiple emulsions, i.e. those which themselves contain droplets of a further dispersed phase in the droplets of the dispersed (or discontinuous) phase, e.g. W / O / W emulsions and O / W / O emulsions.
- emulsifiers In order to guarantee the metastability of emulsions, surface-active substances, i.e. emulsifiers, are generally necessary.
- emulsifier-free preparations which, for example, have oil droplets dispersed in an aqueous phase, similar to an O / W emulsion.
- a prerequisite for this may be that the continuous aqueous phase has a gel structure stabilizing the dispersed phase and other circumstances more.
- Such systems are sometimes called hydrodispersions or oleodispersions, depending on which is the disperse phase and which is the continuous phase.
- Gels are the usual and increasingly popular cosmetic and dermatological preparation forms.
- gels are understood to mean: Relatively dimensionally stable, easily deformable disperse systems composed of at least two components, which as a rule consist of a - usually solid - colloidally divided substance made up of long-chain molecular groups (e.g. gelatin, silica, polysaccharides) as a scaffold and a liquid dispersant (e.g. water) exist.
- the colloidally divided substance is often referred to as a thickening or gelling agent. It forms a spatial network in the dispersant, whereby individual colloidal particles are involved via electrostatic interaction.
- T ⁇ TIGINGSKOPIE can be more or less firmly linked.
- the dispersing agent that surrounds the network is characterized by electrostatic affinity for the gelling agent, ie a predominantly polar (in particular: hydrophilic) gelling agent preferably gels a polar dispersing agent (in particular: water), whereas a predominantly non-polar gelling agent preferably gels non-polar dispersing agent.
- Lipogels and oleols are also common in cosmetic and pharmaceutical galenics.
- oleogels which are practically anhydrous
- hydrogels which are practically fat-free.
- gels are transparent.
- gels are usually characterized by a semi-solid, often flowable consistency.
- surfactant gels are also common preparations of the prior art. This is understood to mean systems which, in addition to water, have a high concentration of emulsifiers, typically more than about 25% by weight, based on the overall composition. If oil components are solubilized in these surfactant gels, also called “surfactant gels” in technical terms, microemulsion gels are obtained, which are also referred to as “ringing gels”. By adding nonionic emulsifiers, for example alkyl polyglycosides, it is possible to obtain cosmetically more elegant microemulsion gels.
- the cooling effect of cosmetic preparations has so far been based on two basic principles: Use of components which volatilize in gaseous form after topical application and remove the required amount of energy, the so-called enthalpy of vaporization, for the most part from the skin surface. Suitable liquid components are therefore used in corresponding non-occlusive cosmetics. Ethanol has proven to be particularly suitable here, and formulations with a high water content also have a clear cooling effect.
- cooling agents that interact with the skin's heat receptors and thus trigger a feeling of cold without generating a measurable physical cooling.
- menthol and various menthol derivatives are used for this.
- high ethanol contents as well as menthol and its derivatives are not suitable for numerous applications from an olfactory point of view, in addition to their irritative potential, in particular because of their distinct odor. Frequently enough, such substances also cause an increase in blood circulation, which on the contrary creates a feeling of warmth.
- cooling agents In the literature, for example, ionic compounds, especially ammonium salts, are described as cooling agents. Isopropanolic gels with camphor and menthol additives are also widely used as cooling preparations.
- the object of the present invention was therefore to provide nourishing cosmetic and medical preparations which do not have the disadvantages of the prior art, in particular those which, when applied to the skin or mucous membranes, have a moisturizing and / or cooling effect.
- phase transition from the solid to the liquid state is also characterized by the occurrence of heat of transformation in numerous compounds. Endothermic melting processes take place with the absorption of energy that originates from the environment and thus leads to a lowering of the temperature there.
- cooling cosmetic or medical topical preparations characterized by a content of one or more substances, the melting point or melting interval of which is chosen in the range between 28 ° C. and 40 ° C., and the positive enthalpy of fusion have, which substance or substances are present in the preparations in the solid state.
- ° C is selected and which have a positive enthalpy of fusion for the production of cooling cosmetic or medical topical preparations
- preparations according to the invention develop their cooling effect within a wide range of use concentrations of the underlying substances, for example 0.5-50% by weight, advantageously 1-20% by weight, based on the total weight of the preparations. They are easy to formulate and make no great demands on manufacturing processes.
- lipophilic substances are selected whose melting point or melting interval is in the range between 28 ° C and 40 ° C and which have a positive enthalpy of fusion
- hydrophilic cosmetic or dermatological bases are to be considered to which the substance or as the substances whose melting point or melting interval is in the range between 28 ° C. and 40 ° C. and which have a positive enthalpy of fusion are then particularly preferably in particulate suspension, for example in aqueous gel formulations.
- Particularly advantageous substances whose melting point or melting interval is selected in the range between 28 ° C and 40 ° C and which have a positive melting enthalpy are selected from the group of lipophilic substances, in particular the esters of C 14 -C 8 fatty acids, with low molecular weight ( C 1 - C 5 ) alcohols, the fatty alcohols C 8 - C 22 , the branched or unbranched fatty acids, the hydrocarbons C 16 - C 22 .
- Methyl palmitate is particularly preferred for the purposes of the present invention.
- cooling active ingredients for example menthol or menthol derivatives, can be added to these formulations for sensory modification or for enhancing the cooling effect.
- BEST ⁇ TIGINGSKOPIE sen are also collectively referred to in the context of the present disclosure as the active ingredient according to the invention or provided with similar synonyms.
- preparations containing the active compound combinations according to the invention, customary antioxidants can be used.
- the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Carnosine and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g.
- amino acids eg glycine, histidine, tyrosine, tryptophan
- imidazoles eg urocanic acid
- peptides such as D, L-carnosine, D-carnosine, L
- thioredoxin glutathione , Cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) as well as their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
- buthioninsulfoximines homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, hexa- foximin) in very low tolerable doses (e.g.
- chelators eg ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin, hydroxy acids (eg citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA , EGTA and its derivatives, unsaturated fatty acids and their derivatives (eg ⁇ -linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (eg ascorbyl palmitate, Mg-ascorbyl phosphate , Ascorbylacetate), tocopherols and derivatives (eg vitamin E acetate), as well as coniferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and
- hydroxy acids eg citric acid, lactic acid,
- BEST ⁇ TIGINGSKOPIE their derivatives, zinc and their derivatives (for example ZnO, ZnSO 4 ) selenium and their derivatives (for example selenium methionine), stilbenes and their derivatives (for example stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides) , Nucleosides, peptides and lipids) of these active ingredients.
- the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
- the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is carried out in the usual way, namely in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
- the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydro-dispersion or lipodispersion, a gel, a solid stick or an aerosol.
- Emulsions according to the invention in the sense of the present invention are advantageous and contain e.g. Fats, oils, waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
- Medical topical compositions in the sense of the present invention generally contain one or more medicaments in an effective concentration.
- medicaments in an effective concentration.
- cosmetic or topical dermatological compositions within the meaning of the present invention, depending on their structure, can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to add the compositions according to the invention as the basis for pharmaceutical formulations use.
- cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
- these preferably additionally contain at least one UVA filter substance and / or at least one UVB filter substance and / or at least one inorganic pigment.
- UV-A or UV-B filter substances are usually incorporated into day creams.
- Preparations according to the invention can advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the preparations.
- the UVB filters can be oil-soluble or water-soluble.
- oil-soluble substances e.g. to call:
- 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
- Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
- Esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid
- Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;
- Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxy-benzophenone-5-sulfonic acid and their salts;
- UVB filters which can be used according to the invention, is of course not intended to be limiting.
- the invention also relates to the combination of a UVA filter according to the invention with a UVB filter or a cosmetic or dermatological preparation according to the invention which also contains a UVB filter.
- UVA filters in the preparations according to the invention, which are usually contained in cosmetic and / or dermatological preparations.
- Such filter substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- ( 4'-isopropylphenyl) propane-1,3-dione.
- Preparations containing these combinations are also the subject of the invention.
- the same amounts of UVA filter substances that were mentioned for UVB filter substances can be used.
- Cosmetic and / or dermatological preparations in the sense of the present invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. The amounts given for the above combinations can be used.
- the cosmetic preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, for example preservatives, bactericides, deodorising substances, antiperspirants, insect repellents, vitamins, agents for preventing foaming, dyes, pigments with a coloring effect, thickeners, softening substances , moisturizing and / or moisturizing substances, fats, oils, waxes or other usual substances components of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
- cosmetic auxiliaries as are usually used in such preparations, for example preservatives, bactericides, deodorising substances, antiperspirants, insect repellents, vitamins, agents for preventing foaming, dyes, pigments with a coloring effect, thickeners, softening substances , moisturizing and / or moisturizing substances, fats, oils, waxes or other usual substances components of a cosmetic formulation such as alcohols, polyols, polymers
- Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to prepare cosmetic preparations To provide that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair.
- the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to prepare cosmetic preparations To provide that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair.
- UVB filter substances if they contain UVB filter substances, they can be oil-soluble or water-soluble.
- Oil-soluble UVB filters which are advantageous according to the invention are, for example:
- 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
- Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
- esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
- Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester,
- Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and also the sulfonic acid itself;
- BEST ⁇ TIG ⁇ NGSKOPIE Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxy-benzophenone-5-sulfonic acid and their salts;
- Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene-methyl) sulfonic acid and their salts and 1,4-di (2-oxo-10-sulfo 3-bornylidene methyl) -benzene and its salts (the corresponding 10-sulfato compounds, e.g. the corresponding sodium, potassium or triethanolammonium salt), also as benzene-1,4-di (2-oxo-3-bornylidene methyl) Designated 10-sulfonic acid
- UVB filters which can be used in combination with the active compound combinations according to the invention, is of course not intended to be limiting.
- UVA filters that are usually contained in cosmetic preparations.
- These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1,3-dione.
- the quantities used for the UVB combination can be used.
- Cosmetic and dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (Ti0 2 ), zinc (ZnO), iron (eg Fe 2 0 3 ), zirconium (Zr0 2 ), silicon (Si0 2 ), manganese (eg MnO), aluminum (Al 2 0 3 ), cerium (eg Ce 2 0 3 ), mixed oxides of the corresponding metals and mixtures of such oxides. It is particularly preferred to use pigments based on TiO 2 .
- the inorganic pigments are in hydrophobic form, i.e. that they have been treated to be water-repellent on the surface.
- This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se.
- BEST ⁇ TIGINGSKOPIE One such method consists, for example, in that the hydrophobic surface layer after a rectification
- n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals.
- hydrophobized pigments shown in analogy to DE-OS 33 14 742 are advantageous.
- Advantageous Ti0 2 pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
- Preparations according to the invention can also contain anionic, nonionic and / or amphoteric surfactants, especially if crystalline or microcrystalline solids, for example inorganic micropigments, are to be incorporated into the preparations according to the invention.
- Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
- hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -0S0 3 2" , -S0 3 " , while the hydrophobic parts generally represent non-polar hydrocarbon residues.
- Surfactants are generally classified according to Art and charge of the hydrophilic part of the molecule. There are four groups:
- Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In water
- BEST ⁇ TIGIIMGSKOPIE solution they form positively charged organic ions in an acidic or neutral environment.
- Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
- Non-ionic surfactants do not form ions in an aqueous medium.
- acylglutamates for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
- acyl peptides for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed.es soy protein and sodium / potassium cocoyl-hydrolyzed collagen,
- sarcosinates for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
- taurates for example sodium lauroyl taurate and sodium methyl cocoyitaurate
- carboxylic acids for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
- ester carboxylic acids for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauram idcarboxylate,
- ether carboxylic acids for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,
- BEST ⁇ TIGINGSKOPIE Phosphoric acid esters and salts such as DEA-oleth-10-phosphate and dilureth-4-phosphate,
- acyl isethionates e.g. Sodium / ammonium cocoyl isethionate
- alkyl sulfonates for example sodium cocosmonoglyceride sulfate, sodium C 12 . 14 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
- Sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate
- sulfuric acid esters such as
- alkyl ether sulfate for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C 12 . 13 pareth sulfate,
- Alkyl sulfates for example sodium, ammonium and TEA lauryl sulfate.
- Quaternary surfactants contain at least one N atom which is covalently linked to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge.
- Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous.
- the cationic surfactants used in the invention can also preferably be chosen from the group of quaternary ammonium compounds, especially benzyltrialkylammonium chlorides or bromides, such as rylammoniumchlorid Benzyldimethylstea-, further alkyltrialkylammonium salts, for example cetyltrimethylammonium chloride or bromide, niumchloride Alkyldimethylhydroxyethylammo- or bromides, dialkyldimethylammonium chlorides or bromides , Alkyl amide
- BEST ⁇ TIGINGSKOPiE ethyltrimethylammonium ether sulfates alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Cetyltrimethylammonium salts are particularly advantageous.
- acyl / dialkyl ethylenediamine for example sodium acyl amphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acylamphohydroxy propyl sulfonate, disodium acyl amphodiacetate and sodium acyl amphopropionate,
- N-alkylamino acids for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
- alkanolamides such as Cocamide MEA / DEA MIPA
- amine oxides such as cocoamidopropylamine oxide
- esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
- ethers for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterol esters, ethoxylated / propoxylated triglyceride esters, ethoxylated.es propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, and propoxylated POE ethers Alkyl polyglycosides such as lauryl glucoside, decyl glycoside and cocoglycoside.
- the surface-active substance can be present in the preparations according to the invention in a concentration between 1 and 95% by weight, based on the total weight of the preparations.
- Oils such as triglycerides of capric or caprylic acid as well as natural oils such as e.g. Castor oil;
- Fats, waxes and other natural and synthetic fat bodies preferably
- Esters of fatty acids with low C alcohols e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with lower C- alkanoic acids
- Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
- the oil phase of the emulsions of the present invention is advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms.
- ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethyl-2-ethylhexyl palmitate 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate and synthetic, semisynthetic and natural mixtures of such esters, for example Jojoba oil.
- the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or
- BEST ⁇ TIGINGSKOPIE saturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 carbon atoms.
- the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
- any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
- the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
- hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
- the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
- Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:
- n can take values from 3/2 to 20. Broken values for n take into account that there may be odd numbers of siloxyl groups in the cycle.
- Cyclomethicone e.g. decamethylcyclopentasiloxane
- silicone oils can also be used advantageously for the purposes of the present invention, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.
- silicone oils of a similar constitution to the compounds described above, the organic side chains of which are derivatized, for example polyethoxylated and / or polypropoxylated.
- these include, for example, polysiloxane-polyalkyl-polyether copolymers such as the cetyl-dimethicone copolyol, the (cetyl-dimethicone copolyol (and) polyglyceryl-4-isostearate (and) hexyl laurate)
- the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, di - Ethylene glycol monomethyl or monoethyl ether and similar products, furthermore alcohols with a low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide and aluminum silicates.
- alcohols, diols or polyols of low C number and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol
- Preparations according to the invention which are present as emulsions particularly advantageously contain one or more hydrocolloids.
- hydrocolloids can advantageously be selected from the group of the gums, polysaccharides, cellulose derivatives, layered silicates, polyacrylates and / or other polymers.
- Preparations according to the invention which are present as hydrogels contain one or more hydrocolloids. These hydrocolloids can advantageously be selected from the aforementioned group.
- Gums include plant or tree sap that harden in the air and form resins or extracts from aquatic plants. Gum arabic, locust bean gum, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, algine, chondrus, xanthan gum can advantageously be selected from this group for the purposes of the present invention.
- derivatized gums such as hydroxypropyl guar (Jaguar® HP 8) is also advantageous.
- polysaccharides and derivatives are e.g. Hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
- cellulose derivatives are e.g. Methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose.
- Layered silicates contain naturally occurring and synthetic clays such as Montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Veegum®. These can be used as such or in a modified form such as e.g. Stearylalkonium hektorite.
- silica gels can also advantageously be used.
- the polyacrylates include e.g. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).
- polymers e.g. Polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols.
- Preparations according to the invention in the form of emulsions contain one or more emulsifiers.
- emulsifiers can advantageously be selected from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
- the nonionic emulsifiers include a) partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives (e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearyl citrates, b) ethoxylated fatty alcohols and fatty acids c) alkyl acid phenol amide fatty amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, e.g. Triton X)
- the anionic emulsifiers include a) soaps (e.g. sodium stearate) b) fatty alcohol sulfates c) mono-, di- and trialkylphosphonic acid esters and their ethoxylates
- the cationic emulsifiers include a) quaternary ammonium compounds with a long-chain aliphatic radical, e.g. Distearyldimonium Chloride
- amphoteric emulsifiers include a) alkylamininoalkane carboxylic acids b) betaines, sulfobetaines c) imidazoline derivatives
- emulsifiers which include beeswax, wool wax, lecithin and sterols.
- O / W emulsifiers can, for example, advantageously be selected from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example: the fatty alcohol ethoxylates of the ethoxylated wool wax alcohols, the polyethylene glycol ethers of the general formula R-0 - (- CH 2 -CH 2 - 0-) n -R ', the fatty acid ethoxylates of the general formula
- the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers used are selected with particular advantage from the group of substances with HLB values of 11-18, particularly preferably
- fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
- cetyl alcohols cetylstearyl alcohols
- cetearyl alcohols cetearyl alcohols
- Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolureth-12).
- Sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
- Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
- polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl 20-caprate / caprin ) glyceryl oleate, polyethylene glycol (20) glyceryl iso stearate, polyethylene glycol (18) glyceryl oleate / cocoate.
- sorbitan esters from the group polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
- W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18, carbon atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 C atoms, monoglycerol ethers saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12 - 18 C - Atoms, diglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and /
- W / O emulsifiers are glyceryl monostearate, glyceryl monoisostearate, glyceryl monomyristate, glyceryl monooleate, diglyceryl monostearate, diglyceryl
- BEST ⁇ TIGINGSKOPiE monoisostearate colmonocaprylat propylene glycol monostearate, propylene glycol monoisostearate glycol, propylene, sorbitan monoisostearate, propylene glycol monolaurate Sorbitanmo-, sorbitan, Sorbitanmonoisooleat, sucrose distearate, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol, Isobehenylalkohol, Selachyl- alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth 2), glyceryl mono laurate, glyceryl monocaprinate, glyceryl monocaprylate.
- phases (A) and (B) are combined at about 80 ° C and stirred until the phases appear homogeneous. Then phases (A) and (B) are combined and cooled to approx. 40 ° C. The perfume phase (C) is added to the combined phases (A) and (B) at about 40 ° C., whereupon the mixture is cooled to room temperature.
- phases (A) and (B) are combined at approx. 70 - 75 ° C and stirred until the phases appear homogeneous.
- the phases (A) and (B) are then combined and cooled to about 60 ° C., where they are emulsified by vigorous stirring.
- the preservation phase (C) is added to the combined phases (A) and (B) at about 50 ° C., whereupon the entire mixture is cooled to room temperature with continued stirring.
- phases (A) and (B) are combined at approx. 70 - 75 ° C and stirred until the phases appear homogeneous.
- the phases (A) and (B) are then combined and cooled to about 60 ° C., where they are emulsified and homogenized by vigorous stirring.
- the preservation phase (C) is added to the combined phases (A) and (B) at approx. 55 ° C., whereupon the entire mixture is cooled to room temperature with continued stirring.
- phases (A) and (B) are combined at approx. 70 - 75 ° C and stirred until the phases appear homogeneous.
- the phases (A) and (B) are then combined and cooled to about 60 ° C., where they are emulsified and homogenized by vigorous stirring.
- the perfume phase (C) is added to the combined phases (A) and (B) at about 55 ° C., whereupon the entire mixture is cooled to room temperature with continued stirring.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003513517A JP2004536126A (ja) | 2001-07-17 | 2002-07-12 | 長期冷却作用を有する化粧品もしくは皮膚科学的調製物 |
| EP02754879A EP1414398A2 (de) | 2001-07-17 | 2002-07-12 | Kosmetische oder dermatologische zubereitungen mit langanhaltender kühlender wirkung |
| US10/759,946 US20050053632A1 (en) | 2001-07-17 | 2004-01-16 | Cosmetic or dermatological preparations having a long-term cooling action |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10134607.7 | 2001-07-17 | ||
| DE10134607A DE10134607A1 (de) | 2001-07-17 | 2001-07-17 | Kosmetische oder dermatologische Zubereitungen mit langanhaltender kühlender Wirkung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/759,946 Continuation US20050053632A1 (en) | 2001-07-17 | 2004-01-16 | Cosmetic or dermatological preparations having a long-term cooling action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003007908A2 true WO2003007908A2 (de) | 2003-01-30 |
| WO2003007908A3 WO2003007908A3 (de) | 2003-12-04 |
Family
ID=7692002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2002/007784 Ceased WO2003007908A2 (de) | 2001-07-17 | 2002-07-12 | Kosmetische oder dermatologische zubereitungen mit langanhaltender kühlender wirkung |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050053632A1 (de) |
| EP (1) | EP1414398A2 (de) |
| JP (1) | JP2004536126A (de) |
| DE (1) | DE10134607A1 (de) |
| WO (1) | WO2003007908A2 (de) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005177488A (ja) * | 2003-12-17 | 2005-07-07 | Cordis Neurovascular Inc | 活性化可能で生体活性の移植可能な医療装置およびその使用方法 |
| EP1637165A1 (de) | 2004-09-21 | 2006-03-22 | McNeil-PPC, Inc. | Medizinische Emulsionen mit Kühleffekt |
| EP1765259A4 (de) * | 2004-07-01 | 2007-08-01 | E L Management Corp | Kosmetische zusammensetzungen und verfahren mit kühlender wirkung |
| WO2008044154A3 (en) * | 2006-10-10 | 2008-10-23 | Kimberly Clark Co | Skin cooling compositions |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1901631B1 (de) * | 2005-06-16 | 2012-03-21 | Colgate-Palmolive Europe SARL | Deodorant auf wasserbasis und aerosolspender dafür |
| US8029771B2 (en) * | 2007-06-29 | 2011-10-04 | Mary Kay Inc. | Guar gum containing compounds |
| US20090110656A1 (en) * | 2007-10-31 | 2009-04-30 | Lemke Sarah A | Skin cooling composition |
| US20090130042A1 (en) * | 2007-11-16 | 2009-05-21 | Conopco, Inc., D/B/A Unilever | Topical composition |
| US20090157153A1 (en) * | 2007-12-13 | 2009-06-18 | Sarah Anne Lemke | Skin cooling system |
| US9480633B2 (en) | 2011-04-28 | 2016-11-01 | Kimberly-Clark Worldwide, Inc. | Temperature management composition |
| US9084764B2 (en) | 2012-08-16 | 2015-07-21 | Exert Co. | Epidermal cooling |
| CN105377221A (zh) * | 2013-02-27 | 2016-03-02 | Elc管理有限责任公司 | 含有热调节材料的组合物 |
| FR3029777B1 (fr) * | 2014-12-15 | 2019-11-29 | L'oreal | Utilisation de l'association d'un polyether polyurethane non-ionique associatif et d'un derive de cyclohexanol comme agent rafraichissant de la peau |
| CN110035737A (zh) | 2016-05-11 | 2019-07-19 | 拜耳医药保健有限责任公司 | 打成泡沫的凝胶制剂 |
| CA3063190C (en) * | 2017-05-11 | 2023-02-21 | Beiersdorf Ag | Gel sunscreens comprising octyldodecyl/glyceryl hydroxy stearate dimethicone copolymer and fumed silica |
| JP6776301B2 (ja) * | 2018-07-10 | 2020-10-28 | 株式会社カナエテクノス | 外用貼付剤、ゲル基剤の製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605670A (en) * | 1984-02-01 | 1986-08-12 | Nitto Electric Industrial Co., Ltd. | Method for percutaneously administering metoclopramide |
| US4855127A (en) * | 1986-07-07 | 1989-08-08 | Dow Corning Corporation | Lattice-entrapped composition |
| US5026556A (en) * | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| US5674504A (en) * | 1989-07-12 | 1997-10-07 | L'oreal | Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance |
| US5109022A (en) * | 1990-10-24 | 1992-04-28 | Wisconsin Alumni Research Foundation | Non-insecticidal insect repellent |
| DE4312656C2 (de) * | 1993-04-19 | 1996-01-25 | Beiersdorf Ag | Kühlend wirkende kosmetische oder dermatologische Zusammensetzungen |
| EP0734474B1 (de) * | 1993-12-13 | 2002-06-05 | The Procter & Gamble Company | Lotionzusammensetzung fuer papiertuecher |
| FR2720934B1 (fr) * | 1994-06-14 | 1996-07-12 | Oreal | Emulsion nettoyante huile-dans-eau ayant l'aspect d'un lait. |
| FR2721210B1 (fr) * | 1994-06-17 | 1996-08-02 | Oreal | Composition de nettoyage contenant des grains lipidiques. |
| US5601871A (en) * | 1995-02-06 | 1997-02-11 | Krzysik; Duane G. | Soft treated uncreped throughdried tissue |
| US5665426A (en) * | 1995-02-06 | 1997-09-09 | Kimberly-Clark Corporation | Soft treated tissue |
| US5637140A (en) * | 1995-06-21 | 1997-06-10 | Brother Kogyo Kabushiki Kaisha | Water-based ink composition and ink-jet recording process |
| DE69603248T2 (de) * | 1996-01-10 | 1999-11-11 | L'oreal S.A., Paris | Verwendung eines Polyholosids in einer Reinigungs- oder Abschmink-Zusammensetzung und Zusammensetzung, die ein Polyholisid enthält |
| US6187695B1 (en) * | 1998-12-08 | 2001-02-13 | Kimberly-Clark Worldwide, Inc. | Cool feeling tissue product and method |
| US6444219B2 (en) * | 1998-10-09 | 2002-09-03 | Allor Foundation | Antiseptic packaged polyvinylpyrrolidone-cinnamic alcohol solid products and the like and method of preparing the same |
| DE60032899T2 (de) * | 1999-05-21 | 2007-10-25 | Outlast Technologies, Inc., Boulder | Temperaturstabilisierter artikel |
| DE20011491U1 (de) * | 2000-06-30 | 2000-10-12 | Kampffmeyer Mühlen GmbH, 21107 Hamburg | Hautpflegemittel |
| DE60120113T3 (de) * | 2001-04-17 | 2016-04-14 | The Procter & Gamble Company | Erfrischende Zusammensetzugen |
-
2001
- 2001-07-17 DE DE10134607A patent/DE10134607A1/de not_active Withdrawn
-
2002
- 2002-07-12 JP JP2003513517A patent/JP2004536126A/ja active Pending
- 2002-07-12 WO PCT/EP2002/007784 patent/WO2003007908A2/de not_active Ceased
- 2002-07-12 EP EP02754879A patent/EP1414398A2/de not_active Withdrawn
-
2004
- 2004-01-16 US US10/759,946 patent/US20050053632A1/en not_active Abandoned
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005177488A (ja) * | 2003-12-17 | 2005-07-07 | Cordis Neurovascular Inc | 活性化可能で生体活性の移植可能な医療装置およびその使用方法 |
| EP1765259A4 (de) * | 2004-07-01 | 2007-08-01 | E L Management Corp | Kosmetische zusammensetzungen und verfahren mit kühlender wirkung |
| JP2008505110A (ja) * | 2004-07-01 | 2008-02-21 | イーエルシー マネージメント エルエルシー | 化粧品組成物および感覚的冷却方法 |
| EP1637165A1 (de) | 2004-09-21 | 2006-03-22 | McNeil-PPC, Inc. | Medizinische Emulsionen mit Kühleffekt |
| EP2075009A1 (de) * | 2004-09-21 | 2009-07-01 | McNeil-PPC, Inc. | Medizinische Kühlemulsionen |
| WO2008044154A3 (en) * | 2006-10-10 | 2008-10-23 | Kimberly Clark Co | Skin cooling compositions |
| US8039011B2 (en) | 2006-10-10 | 2011-10-18 | Kimberly-Clark Worldwide, Inc. | Skin cooling compositions |
| KR101351177B1 (ko) * | 2006-10-10 | 2014-01-14 | 킴벌리-클라크 월드와이드, 인크. | 피부 냉각 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1414398A2 (de) | 2004-05-06 |
| JP2004536126A (ja) | 2004-12-02 |
| WO2003007908A3 (de) | 2003-12-04 |
| DE10134607A1 (de) | 2003-02-06 |
| US20050053632A1 (en) | 2005-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10223486A1 (de) | Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen | |
| DE10357452A1 (de) | Kosmetische Zubereitungen mit einem Gehalt an Licochalcon A oder einem Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A, und organischen Verdicker | |
| EP3406243B1 (de) | Wirkstoffkombinationen aus licochalcon a oder einem extrakt aus radix glycyrrhizae inflatae, enthaltend licochalcon a, phenoxyethanol und gewünschtenfalls glycerin | |
| EP1414398A2 (de) | Kosmetische oder dermatologische zubereitungen mit langanhaltender kühlender wirkung | |
| EP1696903A1 (de) | Kombination von 2,3-dibenzylbutyrolacton und licochalcon a | |
| EP1401389A2 (de) | Verwendung von carnitin und/oder einem oder mehreren acyl-carnitinen zur herstellung von kosmetischen oder dermatologischen zubereitungen | |
| EP1401387A1 (de) | Carnitin und acyl-carnitinen zur behandlung und prophylaxe von pigmentierungsstörungen | |
| EP0937454A2 (de) | Kosmetische oder dermatologische Zubereitungen, enthaltend Polysaccharide zum Schutze der empfindlichen Haut vor Irritationen | |
| EP1535603B1 (de) | Kosmetische und dermatologische Zubereitung, enthaltend Kreatin und/oder Kreatinin und Elektrolytkonzentrationen mit einer Ionenstärke von mindestens 50 mmol/l | |
| EP1367987A2 (de) | Verwendung von alpha-liponsäuren in kosmetischen oder dermatologischen zubereitungen | |
| DE10034101A1 (de) | Kosmetische oder dermatologische Zubereitungen in Form von Emulsionen, enthaltend Iminodibernsteinsäure | |
| EP1535604B1 (de) | Wirkstoffkombination aus Kreatin und Kreatinin, Phenoxyethanol und Glycerin | |
| EP1449514A1 (de) | Hautpflegeprodukte mit Retinoiden, Ubichinonen sowie Biotin oder Carnitin | |
| EP1392398A2 (de) | Kosmetische und dermatologische zubereitung zur beseitigung und regulation von sebum | |
| DE10217255A1 (de) | Verwendung von Phytochelatinen zur Stabilisierung kosmetischer und/oder dermatologischer Zubereitungen | |
| WO2003007909A2 (de) | Kosmetische oder dermatologische zubereitungen mit langanhaltender kühlender wirkung | |
| DE10050155A1 (de) | Kosemtische und dermatologische Zubereitungen mit einem Gehalt an Desferrioxamin | |
| DE10111048A1 (de) | Verwendung von alpha-Liponsäure zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Regeneration beanspruchter Haut, insbesondere der gealterten Haut | |
| DE20121821U1 (de) | Hautpflegeprodukte mit einer Kombination aus Biotin, Ubichinonen und Cyclodextrinen | |
| WO2002069911A2 (de) | WIRKSTOFFKOMBINATIONEN AUS α-LIPONSÄURE UND BIOCHINONEN | |
| DE10145111A1 (de) | Verwendung von Chitosan zur Stabilisierung kosmetischer und/oder dermatologischer Zubereitungen | |
| DE10207274A1 (de) | Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und alpha-Liponsäure | |
| DE10361213A1 (de) | Verfahren zur Quellung oder Lösung von Carrageenan | |
| DE10146802A1 (de) | Vitaminhaltige Hautpflegeprodukte | |
| DE10139851A1 (de) | Hautpflegeprodukte mit einer Kombination aus Biotin, Ubichinonen und Cyclodextrinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2002754879 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003513517 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10759946 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002754879 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2002754879 Country of ref document: EP |